DOSAGE AND ADMINISTRATION FOR PREVENTING CARDIOTOXICITY IN TREATMENT WITH ERBB2-TARGETED IMMUNOLIPOSOMES COMPRISING ANTHRACYCLIN CHEMOTHERAPEUTIC AGENTS
摘要
Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.
申请公布号
EP2648738(A2)
申请公布日期
2013.10.16
申请号
EP20110847085
申请日期
2011.12.06
申请人
MERRIMACK PHARMACEUTICALS, INC.
发明人
REYNOLDS, JOSEPH, G.;OLIVIER, KENNETH, J.;HENDRIKS, BART, S.;WICKHAM, THOMAS;KLINZ, STEPHAN;GERETTI, ELENA